Literature DB >> 8356052

A recombinant immunotoxin containing a disulfide-stabilized Fv fragment.

U Brinkmann1, Y Reiter, S H Jung, B Lee, I Pastan.   

Abstract

B3(dsFv)-PE38KDEL is a recombinant immunotoxin composed of the Fv region of monoclonal antibody B3 connected to a truncated form of Pseudomonas exotoxin (PE38KDEL), in which the unstable Fv heterodimer (composed of heavy- and light-chain variable regions) is held together and stabilized by a disulfide bond [termed disulfide-stabilized Fv (dsFV)]. A computer modeled structure of the B3(Fv), made by mutating and energy minimizing the amino acid sequence and structure of McPC603, enabled us to identify positions in conserved framework regions that "hypothetically" could be used for disulfide stabilization without changing the structure or affecting antigen binding. This prediction was evaluated experimentally by constructing a disulfide-linked two-chain dsFv-immunotoxin that was produced in Escherichia coli. The activity and specificity of this immunotoxin was indistinguishable from its single-chain Fv (scFv) counterpart, indicating that, as in B3(scFv), the structure of the binding region is retained in B3(dsFv). Because we introduced the stabilizing disulfide bond in between two framework residues in a position that is conserved in most Fv molecules, this method of linkage between the heavy- and light-chain variable regions should be generally applicable to construct immunotoxins and dsFv molecules using other antibodies. Furthermore, the finding that B3(dsFv) was much more stable at 37 degrees C in human plasma than B3(scFv) indicates that dsFvs are possibly more versatile for therapeutic application than scFvs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8356052      PMCID: PMC47177          DOI: 10.1073/pnas.90.16.7538

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   12.779


  20 in total

1.  Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas.

Authors:  I Pastan; E T Lovelace; M G Gallo; A V Rutherford; J L Magnani; M C Willingham
Journal:  Cancer Res       Date:  1991-07-15       Impact factor: 12.701

2.  A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins.

Authors:  V K Chaudhary; J K Batra; M G Gallo; M C Willingham; D J FitzGerald; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

3.  A comparison of strategies to stabilize immunoglobulin Fv-fragments.

Authors:  R Glockshuber; M Malia; I Pfitzinger; A Plückthun
Journal:  Biochemistry       Date:  1990-02-13       Impact factor: 3.162

4.  Single-chain antigen-binding proteins.

Authors:  R E Bird; K D Hardman; J W Jacobson; S Johnson; B M Kaufman; S M Lee; T Lee; S H Pope; G S Riordan; M Whitlow
Journal:  Science       Date:  1988-10-21       Impact factor: 47.728

5.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

6.  Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.

Authors:  J S Huston; D Levinson; M Mudgett-Hunter; M S Tai; J Novotný; M N Margolies; R J Ridge; R E Bruccoleri; E Haber; R Crea
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

7.  A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin.

Authors:  V K Chaudhary; C Queen; R P Junghans; T A Waldmann; D J FitzGerald; I Pastan
Journal:  Nature       Date:  1989-06-01       Impact factor: 49.962

8.  Anti-tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of Pseudomonas exotoxin.

Authors:  L H Pai; J K Batra; D J FitzGerald; M C Willingham; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 12.779

9.  Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli.

Authors:  J Hwang; D J Fitzgerald; S Adhya; I Pastan
Journal:  Cell       Date:  1987-01-16       Impact factor: 66.850

10.  Recombinant immunotoxins containing the VH or VL domain of monoclonal antibody B3 fused to Pseudomonas exotoxin.

Authors:  U Brinkmann; B K Lee; I Pastan
Journal:  J Immunol       Date:  1993-04-01       Impact factor: 5.426

View more
  40 in total

Review 1.  Generation of recombinant antibodies.

Authors:  S M Kipriyanov; M Little
Journal:  Mol Biotechnol       Date:  1999-09       Impact factor: 2.695

2.  Conjugation of an antibody Fv fragment to a virus coat protein: cell-specific targeting of recombinant polyoma-virus-like particles.

Authors:  K Stubenrauch; S Gleiter; U Brinkmann; R Rudolph; H Lilie
Journal:  Biochem J       Date:  2001-06-15       Impact factor: 3.857

3.  Making artificial antibodies: a format for phage display of combinatorial heterodimeric arrays.

Authors:  C Gao; S Mao; C H Lo; P Wirsching; R A Lerner; K D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

Review 4.  Recombinant antibodies for the diagnosis and treatment of cancer.

Authors:  Jürgen Krauss
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

5.  Fluorescent Citrine-IgG fusion proteins produced in mammalian cells.

Authors:  Alexander K Haas; Christoffer von Schwerin; Daniela Matscheko; Ulrich Brinkmann
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857

Review 6.  Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.

Authors:  Robert J Kreitman; Ira Pastan
Journal:  Clin Cancer Res       Date:  2011-10-15       Impact factor: 12.531

7.  Disulfide-stabilized single-chain antibody-targeted superantigen: construction of a prokaryotic expression system and its functional analysis.

Authors:  Jian-Li Wang; Yu-Ling Zheng; Ru Ma; Bao-Li Wang; Ai-Guang Guo; Yong-Qiang Jiang
Journal:  World J Gastroenterol       Date:  2005-08-21       Impact factor: 5.742

8.  Remodeling domain interfaces to enhance heterodimer formation.

Authors:  Z Zhu; L G Presta; G Zapata; P Carter
Journal:  Protein Sci       Date:  1997-04       Impact factor: 6.725

Review 9.  Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.

Authors:  Cédric Rossi; Marie-Lorraine Chrétien; René-Olivier Casasnovas
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

10.  Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model.

Authors:  I H Pastan; G E Archer; R E McLendon; H S Friedman; H E Fuchs; Q C Wang; L H Pai; J Herndon; D D Bigner
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.